Nutrilab, Inc. v. Schweiker

713 F.2d 335
Court of Appeals for the Seventh Circuit·Decided August 8, 1983·No. Nos. 82-2746, 82-2747·Published·Cited by 18 cases

Opinion

CUMMINGS, Chief Judge.

Plaintiffs manufacture and market a product known as “starch blockers” which “block” the human body’s digestion of starch as an aid in controlling weight. On July 1, 1982, the Food and Drug Administration (“FDA”) classified starch blockers as “drugs” and requested that all such products be removed from the market until FDA approval was received. The next day plaintiffs filed two separate complaints in the district court seeking declaratory judgments that these products are foods under 21 U.S.C. § 321(f) and not drugs under 21 U.S.C. § 321(g). The cases were consolidated and the government counterclaimed for a temporary restraining order, which was denied. At the close of the hearing on the preliminary injunction, the parties stipulated to advancing the hearing as a trial on the merits. On October 5, 1982, the district court held that starch blockers were drugs under 21 U.S.C. § 321(g), plaintiffs were permanently enjoined from manufacturing and distributing the products, and they were ordered to destroy existing inventories. Nutrilab, Inc. v. Schweiker, 547 F.Supp. 880 (N.D.Ill.1982). The portion of the order requiring destruction of the products was stayed pending appeal.

The only issue on appeal is whether starch blockers are foods or drugs under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq. Starch blocker tablets and capsules consist of a protein which is extracted from a certain type of raw kidney [336]*336bean. That particular protein functions as an alpha-amylase inhibitor; alpha-amylase is an enzyme produced by the body which is utilized in digesting starch. When starch blockers are ingested during a meal, the protein acts to prevent the alpha-amylase enzyme from acting, thus allowing the undigested starch to pass through the body and avoiding the calories that would be realized from its digestion.

Kidney beans, from which alpha-amylase inhibitor is derived, are dangerous if eaten raw. By August 1982, FDA had received seventy-five reports of adverse effects on people who had taken starch blockers, including complaints of gastro-intestinal distress such as bloating, nausea, abdominal pain, constipation and vomiting. Because plaintiffs consider starch blockers to be food, no testing as required to obtain FDA approval as a new drug has taken place. If starch blockers were drugs, the manufacturers would be required to file a new drug application pursuant to 21 U.S.C. § 355 and remove the product from the marketplace until approved as a drug by the FDA.

The statutory scheme under the Food, Drug, and Cosmetic Act is a complicated one. Section 321(g)(1) provides that the term “drug” means

* * * (B) articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals; and (C) articles (other than food) intended to affect the structure or any function of the body of man or other animals; and (D) articles intended for use as a component of any article specified in clauses (A), (B), or (C) of this paragraph; but does not include devices or their components, parts, or accessories.

The term “food” as defined in Section 321(f) means

(1) articles used for food or drink for man or other animals, (2) chewing gum, and (3) articles used for components of any such article.

Section 321(g)(1)(C) was added to the statute in 1938 to expand the definition of “drug.” The amendment was necessary because certain articles intended by manufacturers to be used as drugs did not fit within the “disease” requirement of Section 321(g)(1)(B). Obesity in particular was not considered a disease. Thus “anti-fat remedies” marketed with claims of “slenderizing effects” had escaped regulation under the prior definition. See Food, Drags, and Cosmetics: Hearings on S. 1944 before Sub-comm. of Sen. Comm, on Commerce, 73d Cong., 2d Sess. 15-16 (1933) (Statement of Walter G. Campbell, Chief of FDA), reprinted in 1 Legislative History of Food, Drug and Cosmetic Act 105, 107-108 (hereinafter “L.H.F.D.C.A."). The purpose of part C in Section 321(g)(1) supra was “to make possible the regulation of a great many products that have been found on the market that cannot be alleged to be treatments for diseased conditions.” Id.

It is well established that the definitions of food and drug are normally not mutually exclusive; an article that happens to be a food but is intended for use in the treatment of disease fits squarely within the drug definition in part B of Section 321(g)(1) and may be regulated as such. See, eg., National Nutritional Foods Ass’n v. Mathews, 557 F.2d 325, 334 (2d Cir.1977); United States v. Hohensee, 243 F.2d 367 (3d Cir.1957) (tea leaves); United States v. 250 Jars of United States Fancy Pure Honey, 218 F.Supp. 208, 211 (E.D.Mich.1963), affirmed, 344 F.2d 288 (6th Cir.1965). See also S.Rep. No. 493, 73d Cong., 2d Sess. 2 (1934), reprinted in 2 L.H.F.D.C.A. 721, 722 (provision providing that the definition of food, drug, and cosmetic not be construed as mutually exclusive was deleted because language was superfluous); S.Rep. No. 361, 74th Cong., 1st Sess. 4 (1935), reprinted in 3 L.H.F.D.C.A. 660, 663. Under part C of the statutory drug definition, however, “articles (other than food)” are expressly excluded from the drug definition (as are devices) in Section 321(g)(1). Cf. United States v. “Vitasafe Formula M,” 226 F.Supp. 266, 278 (D.N.J.1964) (article is food and drug; but it is unclear whether court applied drug definition in Section 321(g)(1)(B) or (Q). In order to decide if starch blockers are drugs under Section 321(g)(1)(C), therefore, [337]*337we must decide if they are foods within the meaning of the part C “other than food” parenthetical exception to Section 321(g)(1)(C). And in order to decide the meaning of “food” in that parenthetical exception, we must first decide the meaning of “food” in Section 321(f).

Congress defined “food” in Section 321(f) as “articles used as food.” This definition is not too helpful, but it does emphasize that “food” is to be defined in terms of its function as food, rather than in terms of its source, biochemical composition or ingestibility. Plaintiffs’ argument that starch blockers are food because they are derived from food — kidney beans — is not convincing; if Congress intended food to mean articles derived from food it would have so specified. Indeed some articles that are derived from food are indisputably not food, such as caffeine and penicillin. In addition, all articles that are classed biochemically as proteins cannot be food either, because for example insulin, botulism toxin, human hair and influenza virus are proteins that are clearly not food.

Plaintiffs argue that 21 U.S.C. § 343

Free access — add to your briefcase to read the full text and ask questions with AI

Nutrilab, Inc. v. Schweiker, 713 F.2d 335 (7th Cir. 1983).

713 F.2d 335 (Nutrilab, Inc. v. Schweiker) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

United States v. Lebeau
654 F. App'x 826 (Seventh Circuit, 2016)
Allergan, Inc. v. Crawford
398 F. Supp. 2d 13 (District of Columbia, 2005)
Meza v. Southern California Physicians Insurance Exchange
62 Cal. App. 4th 709 (California Court of Appeal, 1998)
United States v. Ten Cartons, Ener-B Nasal Gel
888 F. Supp. 381 (E.D. New York, 1995)
United States v. Kasz Enterprises, Inc.
855 F. Supp. 534 (D. Rhode Island, 1994)
United States v. 789 Cases, More or Less
799 F. Supp. 1275 (D. Puerto Rico, 1992)
United States v. Pro-Ag, Inc.
796 F. Supp. 1219 (D. Minnesota, 1991)
Kellogg Co. v. Mattox
763 F. Supp. 1369 (N.D. Texas, 1991)
United States v. Two Plastic Drums
761 F. Supp. 70 (C.D. Illinois, 1991)
American Health Products Co. v. Hayes
744 F.2d 912 (Second Circuit, 1984)
American Health Products Co., Inc. v. Hayes
574 F. Supp. 1498 (S.D. New York, 1983)
Nutrilab, Inc. v. Schweiker
713 F.2d 335 (Seventh Circuit, 1983)